Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Clinical implications of determination of plasma haloperidol levels.

Santos JL, Cabranes JA, Almoguera I, Ramos JA, Vazquez C, Angeles F.

Acta Psychiatr Scand. 1989 Apr;79(4):348-54.

PMID:
2735205
2.

Haloperidol plasma levels and acute clinical change in schizophrenia.

Coryell W, Kelly M, Perry PJ, Miller DD.

J Clin Psychopharmacol. 1990 Dec;10(6):397-402.

PMID:
2286709
3.

Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.

Santos JL, Ramos JA, Prieto P, Almoguera I, Vazquez C, Rubio ME, Cabranes JA.

Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(6):917-25.

PMID:
2813809
4.

Serum haloperidol concentration and clinical response in schizophrenia.

Kirch DG, Bigelow LB, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ.

Schizophr Bull. 1988;14(2):283-9.

PMID:
3201181
5.

Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.

Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J.

Psychopharmacol Bull. 1990;26(1):13-7.

PMID:
2371368
6.

Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.

Santos JL, Cabranes JA, Vazquez C, Fuentenebro F, Almoguera I, Ramos JA.

Biol Psychiatry. 1989 Aug;26(4):381-8.

PMID:
2669981
7.

Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.

Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, DeJohn C.

Arch Gen Psychiatry. 1984 Nov;41(11):1044-9.

PMID:
6497566
8.

[Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].

Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.

Encephale. 1995 Nov-Dec;21(6):417-24. French.

PMID:
8674466
9.

Haloperidol: therapeutic window in schizophrenia.

Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, Gonzalez-Monclus E.

J Clin Psychopharmacol. 1994 Oct;14(5):303-10.

PMID:
7806684
10.
11.

Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.

Balant-Gorgia AE, Eisele R, Balant L, Garrone G.

Eur Arch Psychiatry Neurol Sci. 1984;234(1):1-4.

PMID:
6489392
12.

Total and free plasma neuroleptic levels in schizophrenic patients.

Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P.

Psychiatry Res. 1984 Dec;13(4):285-93.

PMID:
6596586
13.

Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.

Yasui-Furukori N, Kondo T, Ishida M, Furukori H, Suzuki A, Kaneko S, Inoue M, Otani K.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):53-7.

PMID:
11853119
14.

Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.

Smith RC, Baumgartner R, Shvartsburd A, Ravichandran GK, Vroulis G, Mauldin M.

Psychopharmacology (Berl). 1985;85(4):449-55.

PMID:
2862652
15.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
16.

Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.

Louza Neto MR, Müller-Spahn F, Rüther E, Scherer J.

Pharmacopsychiatry. 1988 Sep;21(5):226-31.

PMID:
3227054
17.
18.

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.

Ulrich S, Neuhof S, Braun V, Meyer FP.

Int Clin Psychopharmacol. 1999 Jul;14(4):219-28.

PMID:
10468314
19.
20.

Correlates of rapid neuroleptic response in male patients with schizophrenia.

Petrie EC, Faustman WO, Moses JA, Lombrozo L, Csernansky JG.

Psychiatry Res. 1990 Aug;33(2):171-7.

PMID:
2243894

Supplemental Content

Support Center